文献速递血管炎

血管炎管理的演变格局:过去、现在与新兴方向

The evolving landscape of vasculitis management: past, current and emerging.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本文回顾了ANCA血管炎从自身抗体发现到固有免疫和适应性免疫多重改变的认识进展,总结了B细胞和T细胞亚群偏移、MPO和PR3自身抗原表达受染色质修饰影响及DNA甲基化变化可能预测持续缓解。治疗方面,针对白细胞介素的单克隆抗体和靶向固有免疫系统的补体抑制剂等新选择正在出现,管理正快速转向更具靶向性、毒性更低的疗法。

要点

  • ANCA血管炎患者B细胞和T细胞亚群偏移,倾向促炎表型。
  • MPO和PR3自身抗原表达受染色质修饰改变影响,DNA甲基化变化可能预测持续缓解。
  • 针对白细胞介素的单克隆抗体和靶向固有免疫系统的补体抑制剂等治疗选择正在出现。

核心结论

  • ANCA血管炎管理正快速转向更具靶向性、毒性更低的疗法,有望实现健康的维持乃至恢复。

研究设计与样本

  • 本文为综述,基于第21届国际血管炎研讨会(巴塞罗那)内容,总结ANCA血管炎发病机制与治疗进展。

主要发现

  • ANCA血管炎患者B细胞和T细胞亚群偏移,倾向促炎表型。
  • MPO和PR3自身抗原表达受染色质修饰改变影响。
  • DNA甲基化变化可能预测血管炎患者持续缓解的可能性。
  • 针对白细胞介素的单克隆抗体已可用,靶向固有免疫系统的补体抑制剂也已可用。
  • 部分患者停药后无复发,处于长期无治疗缓解(LTROT)状态。

临床怎么用

  • 应对固有免疫反应可能对减轻疾病发作时的急性炎症反应和限制后续损伤很重要,尤其在肾小球肾炎患者中。
  • 随着治疗选择扩展,何时停止治疗仍是重要考虑。
  • 未来治疗可能源于对LTROT潜在免疫表型的理解,并开发无需全局免疫抑制即可实现持久缓解的靶向疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our understanding of ANCA vasculitis has advanced from discovery of putative auto-antibodies to a greater understanding of the myriad alterations of innate and adaptive immunity in this disease. The 21st International Vasculitis Workshop held in Barcelona served again as a forum for distributing and sharing advances in this field. B-cell and T-cell subsets are skewed in ANCA vasculitis patients, favoring a pro-inflammatory phenotype. Autoantigen expression of myeloperoxidase (MPO) and proteinase-3 (PR3) is influenced by alterations in chromatin modifications. Changes in DNA methylation may predict the likelihood of sustained remission in vasculitis patients. As our knowledge of disease pathogenesis and disease persistence have progressed, so too has our therapeutic armamentarium. Treatment options are emerging across a variety of immune targets, including the innate and adaptive immune system. Monoclonal antibodies targeting interleukins are available as are complement inhibitors that target the innate immune system. Addressing innate immune responses may be important to abate acute inflammatory responses at disease onset and limit subsequent damage, especially in patients with glomerulonephritis. With expanding therapeutic options, an important consideration remains as to when to stop therapy. A subset of patients discontinue therapy and remain off treatment without relapse, a state of long-term remission off therapy (LTROT). Future therapeutics could be derived from understanding the underlying immunological phenotype in LTROT and developing targeted therapies for durable remission without global immunosuppression. Management of ANCA vasculitis is moving rapidly towards more targeted, less toxic therapies that will optimistically lead to preservation, and perhaps restoration of health.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Falk RJ, Free ME, Ciavatta DJ, et al. The evolving landscape of vasculitis management: past, current and emerging. Rheumatology (Oxford). 2025. PMID: 40071421. doi:10.1093/rheumatology/keae613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。